Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 23, Issue 3, Pages 185-202
http://dx.doi.org/10.1155/2009/201430
Special Article

Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease

Daniel C Sadowski,1 Charles N Bernstein,2 Alain Bitton,3 Ken Croitoru,4 Richard N Fedorak,5 Anne Griffiths,4 and the CAG Crohn’s Consensus Group

1Royal Alexandra Hospital, Edmonton, Alberta, Canada
2University of Manitoba, Winnipeg, Manitoba, Canada
3McGill University, Montreal, Quebec, Canada
4University of Toronto, Toronto, Ontario, Canada
5University of Alberta, Edmonton, Alberta, Canada

Received 30 December 2008; Accepted 8 January 2009

Copyright © 2009 Canadian Association of Gastroenterology. This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution, and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.

How to Cite this Article

Daniel C Sadowski, Charles N Bernstein, Alain Bitton, et al., “Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease,” Canadian Journal of Gastroenterology, vol. 23, no. 3, pp. 185-202, 2009. https://doi.org/10.1155/2009/201430.